默克集团Merck Group（MRK）2018年年度报告「FWB」（英文版）（338页）.pdf

1、Science ANNUAL REPORT 2018 is at the heart of every-thing we do.2.2 BILLIONinvested in research and development in 2018.Around 52,000 hearts at Merck beat for science.Employees in 66 countries share a passion for pushing boundaries and making new discoveries.Since 1668,the name Merck has stood for t

2、he positive power of science.Online You can find out what else makes our research hearts beat faster STEFAN OSCHMANNChairman of the Executive Board and CEO“We believe that scientific exploration and responsible entrepreneurship make techno-logical advantages possible that benefit us all.”Key Figures

3、 for 2018MERCK GROUP Key figures 1 Change million20182017 millionin%Net sales14,83614,5173192.2%Operating result(EBIT)21,7272,423 696 28.7%Margin(%of net sales)211.6%16.7%EBITDA23,5284,164 636 15.3%Margin(%of net sales)223.8%28.7%EBITDA pre23,8004,246 446 10.5%Margin(%of net sales)225.6%29.3%Profit

4、after tax3,3962,61578129.9%Earnings per share()7.765.991.7729.5%Earnings per share pre()25.105.92 0.82 13.9%Business free cash flow22,5083,193 685 21.4%1 Fiscal 2017 has been adjusted,see Note(49)“Effects from new accounting standards and other presentation and measurement changes”in the Notes to th

5、e Consolidated Financial Statements.2 Not defined by International Financial Reporting Standard(IFRSs).MERCK GROUPNet sales million2 Not defined by International Financial Reporting Standards(IFRSs).MERCK GROUPEBITDA pre2 million2018114,51715,02412,84511,3632017120162015201414,8364,2464,4903,6303,38

6、820181201712016201520143,8001 Excluding the Consumer Health business divested in fiscal 2018.Key figure for fiscal 2017 adjusted.Business SectorsPerformance MaterialsHealthcareLife ScienceFebruary 21Life Science enhances presence in AsiaIn 2018,we invested in a cell culture facility in South Korea,a